Document:

Exhibit 4.13

 

WARRANT

 

THIS WARRANT AND THE SHARES ISSUABLE UPON
EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES
LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE
OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES
LAWS, OR AN OPINION OF COUNSEL IN A FORM REASONABLY SATISFACTORY TO THE ISSUER THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT
OR APPLICABLE STATE SECURITIES LAWS OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT.

 

 

 

Warrant To Purchase Common Stock

 

	Warrant No.: 12	Number of Shares: 150,000
	 	Warrant Exercise Price: $5.90 per share
	Issuance Date: August 25, 2020	Expiration Date: August 25, 2027

 

Inhibikase Therapeutics,
Inc., a Delaware corporation (the “Company”), hereby certifies that Flagship Consulting, Inc. (the “Holder”),
the registered Holder hereof or its permitted assigns, is entitled, subject to the terms set forth below, to purchase from the
Company upon surrender of this Warrant, at any time or times on or after the Anniversary Date (as defined herein), but not after
11:59 P.M. Eastern Time on the Expiration Date (as defined herein), One Hundred Fifty Thousand (150,000) fully paid and nonassessable
shares of Common Stock (as defined herein) of the Company (the “Warrant Shares”), which vest on the Anniversary
Date at the exercise price per share of Five dollars and ninety cents ($5.90). Upon the written request of the Holder, the Company
shall promptly, but in no event later than three (3) Business Days following the receipt of such notice, confirm in writing to
any such Holder the number of shares of Common Stock available to purchase from the Company upon surrender of this Warrant. The
Holder and the Company agree that notwithstanding any terms to the contrary contained herein, the Holder shall have no right to
exercise this Warrant until the Anniversary Date.

 

Section 1.              Definitions

 

(a)           The
following words and terms as used in this Warrant shall have the following meanings:

 

(i)          “Affiliated Entity” means any general partner of a Person, if such Person is a partnership, or any person
or entity that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or in under common control
with, such Person.

 

(ii)         “Anniversary Date” means August 25, 2021.

 

(iii)        “Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in New
York City or the State of New York are authorized or required by law to remain closed.

 

(iv)        “Common Stock” means (A) the Company’s Common Stock, par value $0.001 per share, and (B) any capital
stock into which such Common Stock shall have been changed or any capital stock resulting from a reclassification of such Common
Stock.

 

    	 	 	 

     

    

 

(v)          “Expiration
Date” means August 25, 2027.

 

(vi)         “Fair Market Value” means, as of any particular date, the VWAP on the Trading Day immediately preceding
the date of the applicable Exercise Notice. If at any time the Common Stock is not listed or quoted for trading on any Trading
Market, the “Fair Market Value” of the Common Stock shall be the fair market value per share as determined by reference
to a valuation of the Common Stock performed within sixty (60) days prior to the applicable Exercise Notice by an independent valuation
firm engaged by the Company at its expense. The determination of such valuation firm shall be final and conclusive.

 

(vii)        “Issuance Date” means August 25, 2020.

 

(viii)       “Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation,
a trust, an unincorporated organization and a government or any department or agency thereof.

 

(ix)          “Securities Act” means the Securities Act of 1933, as amended.

 

(x)           “Trading Day” means a day on which the Common Stock is traded on a Trading Market.

 

(xi)          “Trading Market” means any of the following markets or exchanges on which the Common Stock is listed
or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq
Global Select Market or the New York Stock Exchange, OTCQB or OTCOX (or any successors to any of the foregoing).

 

(xii)         “VWAP” means, for any date, the daily volume weighted average price of the Common Stock for such date
(or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg
L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)).

 

(xiii)        “Warrant” means this Warrant and all Warrants issued in exchange, transfer or replacement thereof.

 

(xiv)        “Warrant Exercise Price” shall be the price set forth on page one of this Warrant or as subsequently
adjusted as provided in Section 8 hereof.

 

(b)         Other Definitional
Provisions.

 

(i)            Except as otherwise specified herein, all references herein (A) to the Company shall be deemed to include the Company’s
successors and (B) to any applicable law defined or referred to herein shall be deemed references to such applicable law as the
same may have been or may be amended or supplemented from time to time.

 

(ii)           When used in this Warrant, the words “herein”, “hereof”, and “hereunder”
and words of similar import, shall refer to this Warrant as a whole and not to any provision of this Warrant, and the words “Section”,
 “Schedule”, and “Exhibit” shall refer to Sections of, and Schedules and Exhibits to, this
Warrant unless otherwise specified.

 

(iii)          Whenever
the context so requires, the neuter gender includes the masculine or feminine, and the singular number includes the plural, and
vice versa.

 

    	 	2	 

     

    

 

Section 2.          Exercisability of Warrant.
The number of shares of Common Stock issuable pursuant to this Warrant vest on the Anniversary Date.

 

Section 3.          Exercise of Warrant.

 

(a)       Subject to the terms and conditions hereof, this Warrant may be exercised by the Holder hereof then registered on the books
of the Company, in whole or in part, at any time on any Business Day on or after the opening of business on such Business Day,
commencing with the Anniversary Date, and prior to 11:59 P.M. Eastern Time on the Expiration Date, by (i) delivery of a written
notice, in the form of the subscription notice attached as Exhibit A hereto (the “Exercise Notice”),
of such Holder’s election to exercise this Warrant, which notice shall specify the number of Warrant Shares to be purchased
which shall not be less than 1,000 shares in each case (or if less than 1,000 shares are available to purchase from the Company
pursuant to this Warrant), such lesser amount (as such minimum number may be adjusted pursuant to Section 8), (ii) payment to the
Company of an amount equal to the Warrant Exercise Price(s) applicable to the Warrant Shares being purchased, multiplied by the
number of Warrant Shares (at the applicable Warrant Exercise Price) as to which this Warrant is being exercised (plus any applicable
issue or transfer taxes) (the “Aggregate Exercise Price”) in cash or wire transfer of immediately available
funds and (iii) the surrender of this Warrant (or an indemnification undertaking with respect to this Warrant in the case of its
loss, theft or destruction) to a common carrier for overnight delivery to the Company as soon as practicable following such date.
Upon delivery of the Exercise Notice and Aggregate Exercise Price referred to in clause (ii) above the Holder of this Warrant shall
be deemed for all corporate purposes to have become the Holder of record of the Warrant Shares with respect to which this Warrant
has been exercised. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this
Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised
in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of
the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of
a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of
Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and any
assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the
purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given
time may be less than the amount stated on the face hereof.

 

(b)      The
Company shall use best efforts to cause the Warrant Shares purchased hereunder to be transmitted by its transfer agent to the
Holder by crediting the account of the Holder’s broker with The Depository Trust Company through its Deposit or
Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such system if there is an
effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the
Holder, and otherwise by physical delivery of a certificate, registered in the Company’s share register in the name of
the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the
address specified by the Holder in the Notice of Exercise by the time and date that is no later than 11:00 am, Eastern time,
on the tenth (10th) Trading Day after the latest of (A) the delivery to the Company of the Notice of Exercise, (B) surrender
of this Warrant (if required) and (C) payment of the Aggregate Exercise Price (such date, the “Warrant Share
Delivery Date”). In no event may the Warrants be settled in cash. If there is no effective registration statement
permitting the resale of the Warrant Shares, then any Warrant Shares delivered upon exercise of this Warrant shall be
restricted shares. The Company has no obligation of any kind to register the Warrant Shares for resale. The Warrant Shares
shall be deemed to have been issued, and the Holder or any other person so designated to be named therein shall be deemed to
have become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised, with payment
to the Company of the Aggregate Exercise Price and all taxes required to be paid by the Holder, if any, pursuant to Section
3(e) prior to the issuance of such shares, having been paid.

 

    	 	3	 

     

    

 

(c)      Unless the rights represented by this Warrant shall have expired or shall have been fully exercised, the Company shall,
as soon as practicable and in no event later than thirty (30) Business Days after any exercise and at its own expense, upon written
request of the Holder issue a new Warrant identical in all respects to this Warrant exercised except it shall represent rights
to purchase the number of Warrant Shares purchasable immediately prior to such exercise under this Warrant exercised, less the
number of Warrant Shares with respect to which such Warrant is exercised.

 

(d)      No fractional Warrant Shares are to be issued upon any exercise of this Warrant, but rather the number of Warrant Shares
issued upon such exercise of this Warrant shall be rounded up or down to the nearest whole number.

 

(e)      Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such
Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however,
that, in the event Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Warrant Power in the form attached hereto as Exhibit B duly executed by the Holder,
and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental
thereto.

 

(f)       If at any time the Company proposes to merge or consolidate with or into any other corporation, effect any reorganization,
or sell or convey all or substantially all of its assets to any other entity, then, as a condition of such reorganization, consolidation,
merger, sale or conveyance, the Company or its successor, as the case may be, shall enter into a supplemental agreement to make
lawful and adequate provision whereby the Holder shall have the right to receive, upon exercise of this Warrant, the kind and amount
of equity securities which would have been received upon such reorganization, consolidation, merger, sale or conveyance by a Holder
of a number of shares of Common Stock equal to the number of shares issuable upon exercise of this Warrant immediately prior to
such reorganization, consolidation, merger, sale, or conveyance. The Company shall give the Holder of this Warrant ten (10) Business
Days’ prior written notice of the proposed effective date of any such merger, consolidation, reorganization, sale or conveyance,
and the Company shall also give the Holder of this Warrant ten (10) Business Days’ prior written notice of the commencement
of the Company’s voluntary or involuntary dissolution, liquidation or winding up. If the property to be received upon such
merger, consolidation, reorganization, sale or conveyance is not equity securities, and if this Warrant has not been exercised
by or on the effective date of such transaction, it shall terminate.

 

(g)      If, at any time while this Warrant is outstanding, the Company declares or makes any dividend or other distribution of its
assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, shares or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), then, in each
such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated
therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant immediately
before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record
holders of shares of Common Stock are to be determined for the participation in such Distribution.

 

    	 	4	 

     

    

 

(h)      If
at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is
not available for, the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in part,
at such time by means of a “cashless exercise” in lieu of payment to the Company of the Aggregate Exercise Price in
which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)]
by (A), where:

 

(A) = the Fair Market Value;

 

(B) = the Warrant Exercise Price,
as adjusted hereunder; and

 

(X) = the number of Warrant Shares
that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means
of a cash exercise rather than a cashless exercise.

 

If Warrant Shares are
issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities
Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised and the holding period of the Warrant
Shares being issued may be tacked on to the holding period of this Warrant. The Company agrees not to take any position contrary
to this Section 3(h).

 

Section 4.          Covenants
as to Common Stock. The Company hereby covenants and agrees as follows:

 

(a)      
This Warrant is duly authorized and validly issued.

 

(b)      All Warrant Shares which may be issued upon the exercise of the rights represented by this Warrant will, upon issuance,
be validly issued, fully paid and nonassessable and free from all taxes, liens and charges with respect to the issue thereof.

 

(c)       The Company will at all times have authorized and reserved at least one hundred percent (100%) of the number of shares of
Common Stock needed to provide for the exercise of the rights then represented by this Warrant and the par value of said shares
will at all times be less than or equal to the applicable Warrant Exercise Price.

 

(d)      The Company will not, by amendment of its Certificate of Incorporation or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance
or performance of any of the terms to be observed or performed by it hereunder, but will at all times in good faith assist in the
carrying out of all the provisions of this Warrant.

 

Section
5.         Warrant Holder Not Deemed a Stockholder. Except as otherwise
specifically provided herein, no Holder, as such, of this Warrant shall be entitled to vote or receive dividends or be deemed
the holder of shares of capital stock of the Company for any purpose, nor shall anything contained in this Warrant be
construed to confer upon the Holder hereof, as such, any of the rights of a stockholder of the Company or any right to vote,
give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock,
consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or
otherwise, prior to the issuance to the Holder of the Warrant Shares which Holder is then entitled to receive upon the due
exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on
such Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company,
whether such liabilities are asserted by the Company or by creditors of the Company.

 

    	 	5	 

     

    

 

Section 6.         Representations
of Holder. The Holder of this Warrant, by the acceptance hereof, represents that it is acquiring this Warrant and the Warrant
Shares for its own account for investment only and not with a view towards, or for resale in connection with, the public sale or
distribution of this Warrant or the Warrant Shares, except pursuant to sales registered or exempted under the Securities Act; provided,
however, that by making the representations herein, the Holder does not agree to hold this Warrant or any of the Warrant Shares
for any minimum or other specific term and reserves the right to dispose of this Warrant and the Warrant Shares at any time in
accordance with or pursuant to a registration statement or an exemption under the Securities Act and other applicable securities
laws. The Holder of this Warrant further represents, by acceptance hereof, that, as of this date, such Holder is an “accredited
investor” as such term is defined in Rule 501(a)(1) of Regulation D promulgated by the Securities and Exchange Commission
under the Securities Act (an “Accredited Investor”). Upon exercise of this Warrant the Holder shall, if requested
by the Company, confirm in writing, in a form satisfactory to the Company, that the Warrant Shares so purchased are being acquired
solely for the Holder’s own account and not as a nominee for any other party, for investment, and not with a view toward
distribution or resale and that such Holder is an Accredited Investor. If such Holder cannot make such representations because
they would be factually incorrect, it shall be a condition to such Holder’s exercise of this Warrant that the Company receive
such other representations as the Company considers reasonably necessary to assure the Company that the issuance of its securities
upon exercise of this Warrant shall not violate any United States or state securities laws.

 

Section 7.          Ownership and Transfer.

 

(a)       The Company shall maintain at its principal executive offices (or such other office or agency of the Company as it may designate
by notice to the Holder hereof), a register for this Warrant, in which the Company shall record the name and address of the person
or entity in whose name this Warrant has been issued, as well as the name and address of each transferee. The Company may treat
the person in whose name any Warrant is registered on the register as the owner and Holder thereof for all purposes, notwithstanding
any notice to the contrary, but in all events recognizing any transfers made in accordance with the terms of this Warrant.

 

(b)       The Company agrees that, subject to the satisfaction of the conditions set forth in this Section 7(b), the Holder shall
be entitled to transfer all or any portion of this Warrant or of the Warrant Shares (i) in the case that the Holder is an incorporated
or other entity, to an Affiliated Entity of the Holder or (ii) in the case that the Holder is a natural person, for bona fide estate
planning purposes, either during his or her lifetime or on death by will or intestacy to his or her spouse, child (natural or adopted),
or any other direct lineal descendant of such Holder (or his or her spouse) (all of the foregoing collectively referred to as “family
members”), or to any custodian or trustee of any trust, partnership or limited liability company for the benefit of,
or the ownership interests of which are owned wholly by, such Holder or any such family members. The Holder agrees not to make
any transfer or disposition of the Warrant or all or any portion of the Warrant Shares to any Affiliated Entity, family member
or custodian or trustee or to any other Person unless and until (i) the Holder shall have notified the Company of the proposed
disposition and shall have furnished the Company with a reasonably detailed statement of the circumstances surrounding the proposed
disposition and (ii) the transferee has agreed in writing for the benefit of the Company to be bound by the terms of this Warrant
and any other stockholder or similar agreement among substantially all other holders of Common Stock as reasonably requested by
the Company. Any transfer in violation of this Section 7(b) shall be void ab initio.

 

    	 	6	 

     

    

 

Section 8.         Adjustment
of Warrant Exercise Price and Number of Shares. The Warrant Exercise Price and the number of shares of Common Stock issuable
upon exercise of this Warrant shall be adjusted from time to time as follows:

 

(a)       Adjustment
of Warrant Exercise Price upon Subdivision or Combination of Common Stock. If the Company at any time after the date of issuance
of this Warrant subdivides (by any stock split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding
shares of Common Stock into a greater number of shares, any Warrant Exercise Price in effect immediately prior to such subdivision
will be proportionately reduced and the number of shares of Common Stock obtainable upon exercise of this Warrant will be proportionately
increased. If the Company at any time after the date of issuance of this Warrant combines (by combination, reverse stock split
or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, any Warrant Exercise
Price in effect immediately prior to such combination will be proportionately increased and the number of Warrant Shares issuable
upon exercise of this Warrant will be proportionately decreased. Any adjustment under this Section 8(a) shall become effective
at the close of business on the date the subdivision or combination becomes effective.

 

(b)      Notices.
Promptly upon any adjustment of the Warrant Exercise Price, the Company will give written notice thereof to the Holder of this
Warrant, setting forth in reasonable detail, and certifying, the calculation of such adjustment.

 

Section 9.         Mutilated
or Destroyed Warrant. If this Warrant is lost, stolen, mutilated or destroyed, the Company shall promptly, on receipt of an
indemnification undertaking (or, in the case of a mutilated Warrant, the Warrant), issue a new Warrant of like denomination and
tenor as this Warrant so lost, stolen, mutilated or destroyed.

 

Section 10.        Notice.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Warrant must be
in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent
by facsimile (provided confirmation of receipt is received by the sending party transmission is mechanically or electronically
generated and kept on file by the sending party); or (iii) one Business Day after deposit with a nationally recognized overnight
delivery service, in each case properly addressed to the party to receive the same. The addresses and facsimile numbers for such
communications shall be:

 

		If to Holder:	Flagship Consulting, Inc.

131 Daniel Webster Highway

Suite 322

Nashua, NH 03060

Attn: Joseph Frattaroli

 

		If to the Company, to:	Inhibikase Therapeutics, Inc.

3350 Riverwood Parkway,

Suite 1900

Atlanta, GA 30339

Attn: Milton Werner, Ph.D.

President and CEO

 

Each party shall provide five
days’ prior written notice to the other party of any change in address or facsimile number. Written confirmation of
receipt (A) given by the recipient of such notice, consent, facsimile, waiver or other communication, or (B) provided by a
nationally recognized overnight delivery service shall be rebuttable evidence of personal service, receipt by facsimile or
receipt from a nationally recognized overnight delivery service in accordance with clause (i), (ii) or (iii) above,
respectively.

 

    	 	7	 

     

    

 

Section 11.       Date.
The date of this Warrant is set forth on page 1 hereof. This Warrant, in all events, shall be wholly void and of no effect after
the close of business on the Expiration Date.

 

Section 12.        Amendment
and Waiver. Except as otherwise provided herein, the provisions of the Warrants may be amended by a writing executed by both
the Company and the Holder.

 

Section 13.        Descriptive
Headings; Governing Law. The descriptive headings of the several sections and paragraphs of this Warrant are inserted for convenience
only and do not constitute a part of this Warrant. All questions concerning the construction, validity, enforcement and interpretation
of this Warrant shall be governed by the internal laws of the State of Delaware, without giving effect to any choice of law or
conflict of law provision or rule (whether of the State of Delaware or any other jurisdictions) that would cause the application
of the laws of any jurisdictions other than the State of Delaware. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in Delaware, for the adjudication of any dispute hereunder or in connection herewith or
therewith, or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert
in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such
suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action
or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Warrant and agrees that
such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any manner permitted by law.

 

Section 14.       Waiver
of Jury Trial. AS A MATERIAL INDUCEMENT FOR EACH PARTY HERETO TO ENTER INTO THIS WARRANT, THE PARTIES HERETO HEREBY WAIVE
ANY RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING RELATED IN ANY WAY TO THIS WARRANT AND/OR ANY AND ALL OF THE OTHER DOCUMENTS
ASSOCIATED WITH THIS TRANSACTION.

 

Section 15.       Lock-Up
Agreement. If requested by the Company and the representative underwriter, Holder agrees to enter into a lock-up agreement
(the “Lock-Up Agreement”) pursuant to which it will not, for a period set forth in the Lock-up Agreement following
the effective date of the first registration statement of the Company’s initial public offering, offer, sell or otherwise
dispose of the Warrant Shares or any other equity securities of the Company held. The Lock-up Agreement shall provide that the
provisions thereof may be waived with the consent of the Company and the representative underwriter.

 

[signature page follows]

 

    	 	8	 

     

    

 

IN WITNESS WHEREOF,
the Company has caused this Warrant to be signed as of the date first set forth above.

 

 

	Flagship Consulting, Inc.	 	Inhibikase Therapeutics, Inc.
	 	 	 
	 	 	 	 	 
	By:	/s/ Joseph Frattaroli	 	By:	/s/ Milton Werner
	Name:	Joseph Frattaroli	 	Name:	Milton Werner, Ph.D.
	Title:	Authorized Officer	 	Title:	President & Chief Executive Officer

 

    	 	9	 

     

    

 

EXHIBIT A TO WARRANT

 

EXERCISE NOTICE

 

TO BE EXECUTED

BY THE REGISTERED HOLDER TO EXERCISE THIS WARRANT

 

 

 

The undersigned Holder hereby exercises the
right to purchase____________ shares of Common Stock (“Warrant Shares”) of Inhibikase Therapeutics, Inc.,
a Delaware corporation (the “Company”), evidenced by the attached Warrant (the
 “Warrant”). Capitalized terms used herein and not otherwise defined shall have the respective meanings set
forth in the Warrant.

 

1.           
Form of Warrant Exercise Price and Payment. Check applicable box:

 

  ̈
The Holder intends that payment of the Warrant Exercise Price shall be made as a “Cash Exercise” with respect to
______________ Warrant Shares. The Holder shall pay the sum of $______________ to the Company in accordance with the terms of
the Warrant.

 

  ̈
The Holder intends that payment of the Warrant Exercise Price shall be made as a “Cashless Exercise” in
accordance with the formula set forth in Section 3(h), to exercise this Warrant with respect to the maximum number of Warrant
Shares purchasable pursuant to the procedure set forth in Section 3(h).

 

2.           
Delivery of Warrant Shares. The Company shall deliver to the Holder_______________ Warrant Shares in accordance with the terms of the Warrant and will issue said Warrant Shares in the name of the undersigned or
in such other name or names as is specified below:

 

The Warrant Shares shall be delivered to the following
DWAC Account Number:

 

 

[SIGNATURE OF HOLDER:]

 

Name of Holder:_________________________________________

 

Signature
of Authorized Signatory:___________________________

 

Name of Authorized Signatory:________________________

 

Title of Authorized Signatory:_________________________

 

Date:_________________________________________________

 

    	 	A-1	 

     

    

 

EXHIBIT B TO WARRANT

FORM OF WARRANT POWER

 

FOR VALUE RECEIVED,
the undersigned does hereby assign and transfer to ________________, Federal Identification No.__________, a warrant to purchase
____________ shares of the capital stock of Inhibikase Therapeutics, Inc., a Delaware corporation, represented by warrant certificate
no. _____, standing in the name of the undersigned on the books of said corporation. The undersigned does hereby irrevocably
constitute and appoint ______________, attorney to transfer the warrants of said corporation, with full power of substitution in
the premises.

 

	Dated:	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	By:	 
	 	 	Name:	 
	 	 	Title:	 

 

    	 	B-1Exhibit 4.14

 

AMENDED AND RESTATED SECOND CONVERTIBLE

REVOLVING DEMAND PROMISSORY 2020 NOTE

 

Inhibikase Therapeutics, Inc.

 

Atlanta, Georgia

 

THIS AMENDED AND RESTATED SECOND CONVERTIBLE
REVOLVING DEMAND PROMISSORY 2020 NOTE (THE “2020 Note”) AND THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE NOT
AND WILL NOT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), APPLICABLE STATE
SECURITIES LAWS OR APPLICABLE LAWS OF ANY FOREIGN JURISDICTION. THIS 2020 Note HAS BEEN AND SUCH UNDERLYING SECURITIES HAVE BEEN,
AS THE CASE MAY BE, ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE, AND MAY NOT BE OFFERED, SOLD,
PLEDGED, HYPOTHECATED, RENOUNCED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF EITHER (A) AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR, IF APPLICABLE, ANY FOREIGN JURISDICTION OR (B) IN
THE OPINION OF COUNSEL SATISFACTORY TO COMPANY, THE AVAILABILITY OF AN EXEMPTION FROM THE REGISTRATION PROVISIONS OF THE SECURITIES
ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS OR, IF APPLICABLE, ANY FOREIGN JURISDICTION.

 

Except as otherwise defined in the
text hereof, capitalized terms and phrases shall have the meaning ascribed thereto in Section 7 of this 2020 Note.

 

	$686,013	Issue Date: August 31, 2020

 

WHEREAS, Inhibikase
Therapeutics, Inc. (hereinafter, “Maker”) and Flagship Consulting, Inc. (hereinafter, “Payee”)
previously entered into that certain Convertible Revolving Demand Promissory Note dated April 3, 2018 (hereinafter, the “2018
Flagship Note”);

 

WHEREAS, Maker and
Joseph Frattaroli (hereinafter, “Frattaroli”) previously entered into that certain Convertible Revolving Demand Promissory
Note dated April 3, 2018 (hereinafter, the “2018 Frattaroli Note”) to replace the 2018 Flagship Note;

 

WHEREAS, Maker and
Frattaroli previously entered into that certain Second Convertible Revolving Demand Promissory 2019 Note dated December 31,
2019 (hereinafter, the “2019 Frattaroli Note”); and

 

WHEREAS, Maker, Payee
and Frattaroli desire to amend and restate the 2019 Frattaroli Note in its entirety as follows:

 

Maker promises to
pay to Payee the amount of Three Hundred Eighty-six Thousand Thirteen dollars ($386,013) plus an additional sum of up to
Three Hundred Thousand Dollars ($300,000) or such amount as is accrued from time to time by Maker in unpaid fees, accrued
interest and costs incurred for and on its behalf (the “Fees and Costs”) as are from time to time reflected on
Payee’s monthly statements for services rendered (the “Statements”), whichever amount is less (the
 “Principal”), together with interest thereon from and after the date hereof until paid in full, all as provided
in this 2020 Note. Frattaroli, Maker and Payee acknowledge and agree that (i) this 2020 Note is entered into as full
consideration for the 2019 Frattaroli Note and (ii) that Maker has no remaining obligations to Frattaroli or Payee
pursuant to the 2018 Flagship Note, the 2018 Frattaroli Note or the 2019 Frattaroli Note. Maker and Payee agree that the
balance due under this 2020 Note for Fees and Costs shall be updated based on Payee’s Statements as the same are
published from time to time by modifying that certain schedule entitled “Schedule of Fees and Costs,” which is
attached hereto, marked as “Exhibit A,” and made a part hereof, to reflect such updated balance; provided, however,
that such updating shall only serve as a ministerial act in accounting for the Principal amount, and any failure to perform
or delay in performing such updating shall in no event affect the amount due under this 2020 Note.

 

    

     

    

 

1.            Payment
of Principal and Interest.

 

(a)            Payment
in Cash. This 2020 Note is payable either in full or in part until paid in full, as the case may be, without demand and in
immediately available funds, not later than the earlier to occur of either a Significant Transaction or the 31st day
of December, 2021 (either such date, the “Maturity Date”).

 

(b)            Interest.
From and including the Issue Date to and including the date this 2020 Note is paid or otherwise discharged in full, the unpaid
Principal amount of this 2020 Note shall bear simple interest at Five Percent (5%) per annum, computed on the basis of a year of
360 days; provided, however, that upon the occurrence, and during the continuance of an Event of Default hereunder,
this 2020 Note shall bear simple interest at Twelve Percent (12%) per annum, computed on the basis of a year of 360 days.

 

(c)            Tender.
All payments of Principal and interest shall be made in lawful money of the United States of America and shall be made to Payee
via wire transfer or certified check to an account designated by Payee or, if no account is so designated, at Payee’s address
or at such other place as Payee may designate to Maker in writing in accordance with Section 13 of this 2020 Note.

 

2.            Obligation
to Notify. Maker shall notify Payee in writing (a) thirty (30) days in advance
of a Significant Transaction, and (b) provide Payee with any and all documents relating thereto within forty-eight (48) hours
of being requested by Payee, subject to Payee executing with and in favor and to the satisfaction of Maker an agreement pursuant
to which it agrees to restrictions on the disclosure, use and ownership of any and all such documents and information contained
therein. These rights set forth in this Section 2 shall terminate upon the repayment of this 2020 Note in full.

 

3.            Conversion.

 

(a)            Option
to Elect Payment in Conversion Shares.  Notwithstanding any provision of this 2020 Note to the contrary, Payee shall have
the option, exercisable in his sole and absolute discretion at any time commencing with the Issue Date and ending as
of the date on which the Unpaid Balance of this 2020 Note is paid in full, to Convert all or any portion of the Unpaid
Balance as determined on the Conversion Date into Conversion Shares, in such number of Conversion Shares as shall equal that
portion of the Unpaid Balance as Payee may elect in his discretion to be converted, divided by the Conversion Share
Price.

 

    2

     

    

 

(b)            Automatic
Conversion.

 

(i)            Notwithstanding
anything to the contrary in this 2020 Note, if, on or prior to October 31, 2020, the Company consummates an Initial Public
Offering, the then Unpaid Balance of this 2020 Note shall automatically convert into Conversion Shares, in such number of Conversion
Shares as shall equal all of the Unpaid Balance as of the closing of the Initial Public Offering, divided by the Initial Public
Offering Price.

 

(ii)            If
this 2020 Note is automatically converted pursuant to this Section 3(b), written notice shall be delivered to Payee pursuant
to Section 13, notifying Payee of the Initial Public Offering Price, the Unpaid Balance to be converted and the date on which
such conversion is expected to occur and calling upon Payee to surrender to the Company, in the manner and at the place designated,
this 2020 Note. Upon such conversion of this 2020 Note, Payee hereby agrees to execute and deliver to the Company all transaction
documents entered into by other purchasers participating in the Initial Public Offering as requested by the Company. Payee also
agrees to deliver the original of this 2020 Note (or a notice to the effect that the original 2020 Note has been lost, stolen or
destroyed and an agreement acceptable to the Company whereby the Payee agrees to indemnify the Company from any loss incurred by
it in connection with this 2020 Note) at the closing of any Initial Public Offering for cancellation; provided, however,
that upon the closing of an Initial Public Offering occurring on or before October 31, 2020, this 2020 Note shall be deemed
converted and of no further force and effect, whether or not it is delivered for cancellation as set forth in this sentence. Any
conversion of this 2020 Note pursuant to this Section 3(b) shall be deemed to have been made immediately prior to the
closing of the Initial Public Offering and on and after such date the Persons entitled to receive the Conversion Shares upon such
conversion shall be treated for all purposes as the record holder of such Conversion Shares.

 

4.            Prepayment.
This 2020 Note may be prepaid prior to the Maturity Date at the option of Maker in cash, without premium or penalty, at the
Principal amount so to be prepaid, together with interest accrued thereon to the date fixed for such prepayment; provided, however,
that in no event may any such prepayment or other cash payment be made until and unless Maker shall have given prior written
notice of its intent to pay all or any portion of this 2020 Note to Payee, which notice shall be given not less than ten
(10) nor more than thirty (30) days prior to the date fixed for such payment in such notice and shall specify the amount
so to be paid and the date fixed for such payment (the “Notice Period”). Notwithstanding any provision of this
2020 Note to the contrary, during such Notice Period, Payee may exercise Payee’s rights under Section 3(a) of
this 2020 Note to cause the Conversion of all or any part of the Unpaid Balance to Conversion Shares. Subject to the
foregoing, upon the giving of notice of its payment, Maker shall pay on the date therein fixed for any such
payment.

 

5.            Payments
Credited First Against Interest. Notwithstanding any provision in this 2020 Note to
the contrary, any payment of this 2020 Note, whether as a partial payment or in full, will be credited first against accrued interest,
then Principal, in reverse chronological order.

 

    3

     

    

 

6.            Surrender
of 2020 Note. Upon any such partial payment of the Unpaid Balance, this 2020 Note,
at the election of Maker, shall be either (a) surrendered to Maker in exchange for a new 2020 Note in a Principal amount
equal to Unpaid Balance on the 2020 Note surrendered, and otherwise having the same terms and provisions as this 2020 Note (and
for purposes of the foregoing provisions of this Section to be deemed to be the same 2020 Note and not a novation of the
indebtedness represented thereby), or (b) made available to Maker at the principal office of Maker for notation thereon of
the portion thereof so prepaid. Upon payment in full of the amount of the Unpaid Balance, this 2020 Note shall be surrendered
to the Maker for cancellation.

 

7.            Definitions.
For purposes of this 2020 Note, the following terms and phrases shall have the meaning ascribed thereto:

 

(a)            “Common
Stock” shall have the meaning ascribed thereto in Maker’s Certificate of Incorporation, as the same shall have been
or is amended from time to time.

 

(b)            “Conversion”
or “Converted” shall mean the payment and satisfaction of the Unpaid Balance or such portion thereof as provided in
this 2020 Note by Maker’s issuance to Payee of Conversion Shares in accordance with the terms hereof.

 

(c)            “Conversion
Date” shall mean any such date on which all or any portion of the Unpaid Balance shall be paid by Maker at Payee’s
election as provided in this 2020 Note by Maker’s issuance to Payee of Conversion Shares.

 

(d)            “Conversion
Exercise Date” shall mean the date on which the exercise by Payee of his right to cause the payment of all or any portion
of this 2020 Note in Conversion Shares is made effective; provided, however, that the exercise by Payee of his Conversion
right is delivered to Maker in writing.

 

(e)            “Conversion
Share(s)” shall mean that number of Shares of Common Stock to which Payee is entitled in payment, whether in whole or in
part, of the Unpaid Balance in accordance with the terms and conditions of this 2020 Note.

 

(f)            “Conversion
Share Price” shall mean that amount as shall equal the Fair Market Value of each Share of Maker’s Common Stock (as
determined on an as converted and fully diluted basis) as such per Share value and number of Shares of Common Stock are determined
to exist as of the Conversion Exercise Date.

 

(g)            “Fair
Market Value” means, as of the Conversion Exercise Date, the fair market value of a Share of Maker’s Common Stock determined
as follows:

 

(i)            If
the Shares are readily tradable on a Securities Market, by the closing price of a Share on the Conversion Exercise Date as reported
on the composite tape for securities traded on the Securities Market. If a closing price was not reported on that date, then the
arithmetic mean of the high and low prices at the close of the market on that date, and if these prices were not reported on that
date, then the closing price on the last trading day on which a closing price was reported.

 

    4

     

    

 

(ii)            If
Maker’s Board of Directors (the “Board”) in its reasonable discretion determines that the Shares are not readily
tradable on a Securities Market, by an independent written appraisal that satisfies the requirements of Internal Revenue Code
Section 401(a)(28)(C) as of the Conversion Exercise Date (the “Appraisal”).

 

(iii)            Once
the Conversion Share Price has been established, the Board shall not change the same through the retroactive use of another valuation
method.

 

(iv)            Shares
are treated as readily tradable on a Securities Market if they are regularly quoted by brokers or dealers making a market in the
Shares.

 

(h)            “Government
Body” means: (i) the government of any country, or the government of any political subdivision of any country (a “Government”);
(ii) any instrumentality of a Government; (iii) any other Person authorized by Law to perform any administrative, executive,
judicial, legislative, military, police, or regulatory functions of a Government; (iv) any intergovernmental organization;
and (v) any successor to the entities listed under Clauses (i) to (iv).

 

(i)            “Initial
Public Offering” means the first underwritten offering or listing of Shares of Maker or any successor to Maker when such
Shares are offered pursuant to an effective registration statement under the Exchange Act.

 

(j)            “Initial
Public Offering Price” means the price at which the Company’s Common Stock was sold in an Initial Public Offering.

 

(k)            “Law”
means: (i) an administrative decision on which Persons other than those to whom the decision was issued can rely; (ii) a
judicial decision on which Persons other than those to whom the decision was issued can rely; (iii) an ordinance or statute;
(iv) a regulation or rule; or (v) any combination of the items under Clauses (i) to (iv).

 

(l)            “Person”
means an association, business trust, corporation, estate, general partnership, governmental entity or any department or agency
thereof, individual, limited liability company, limited liability partnership, limited partnership, non-profit or charitable organization
or other entity, sole proprietor, trust, unincorporated organization or other entity.

 

(m)            “Securities
Market” means: (i) a national securities exchange that is registered under Section 6 of the Securities Exchange
Act of 1934, as amended; (ii) a foreign national securities exchange that is officially recognized, sanctioned, or supervised
by a Government Body; or (iii) any over-the-counter market that uses an interdealer quotation system. An interdealer quotation
system is any system of general circulation to brokers and dealers that regularly disseminates quotations of stocks and securities
by identified brokers or dealers, other than by quotation sheets that are prepared and distributed by a broker or dealer in the
regular course of business and that contain only quotations of that broker or dealer.

 

(n)            “Share”
means a share of Common Stock.

 

    5

     

    

 

(o)            “Significant
Transaction” shall mean any one of the following:

 

(i)            Any
transaction (or the first tranche of any series of integrated transactions) pursuant to which Maker sells, transfers, leases, exchanges
or disposes of all or substantially all of its assets for cash or property, or for a combination of cash and property, or for other
consideration; or

 

(ii)            Any
transaction, whether in a single or series of related steps, pursuant to which (1) any Person (or group of Persons) acquires
within a twelve (12) consecutive calendar month period by merger, consolidation, reorganization, division or other business combination
or transaction or by a purchase of an interest in Maker such that after any such transaction, the holders of ownership interests
of Maker immediately prior to such transaction no longer have a controlling interest in Maker (or any successor-in-interest thereof);
or (2) the shares of capital stock of Maker or any successor thereto are traded on a Securities Market, whether as a result
of an Initial Public Offering or via a reverse merger by Maker into a company the capital stock of which is traded on a Securities
Market.

 

(p)            “Unpaid
Balance” shall mean the amount of accrued and outstanding, but unpaid Principal and such amount of interest as shall have
accrued thereon as provided in Section 1 of this 2020 Note through and including any date fixed for payment, whether in whole
or in part, under this 2020 Note.

 

8.            No
Fractional Shares. Instead of any fractional Conversion Shares that would otherwise
be issuable upon conversion of this 2020 Note, Maker shall pay a cash adjustment in respect of such fractional interest in an amount
equal to the product of (a) the Conversion Share Price or Initial Public Offering Price as applicable, and (b) such fractional
interest. The holder of fractional interests shall not be entitled to any rights as security holders of Maker in respect of such
fractional interests.

 

9.            No
Impairment. Maker shall not, by amendment of its Certificate of Incorporation or
Bylaws, each as amended to date, or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue
or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms
of this 2020 Note, but shall at all times in good faith assist in the carrying out of all such terms and in the taking
of all such action as may be necessary or appropriate in order to protect the rights of Payee against dilution or other
impairment.

 

10.            Events
of Default. The occurrence or existence of any one of the following events or conditions
shall constitute an “Event of Default”:

 

(a)            Maker
shall fail to pay the Principal of, or interest on, this 2020 Note when the same becomes due and payable in accordance with the
terms hereof and such amount remains unpaid for ten (10) business days after the due date thereof;

 

(b)            Maker
fails to observe or perform any other covenant or agreement on the part of Maker contained in this 2020 Note which failure continues
for a period of thirty (30) days (except in the case of its obligation under Section 3 of this 2020 Note, in which case the
period shall be three (3) days) after the date of written notice thereof from Payee; or

 

(c)            Maker
makes a general assignment for the benefit of its creditors or applies to any tribunal for the appointment of a trustee or receiver
of a substantial part of the assets of Maker, or commences any proceedings relating to Maker under any bankruptcy, reorganization,
arrangement, insolvency, readjustment of debts, dissolution or other liquidation law of any jurisdiction; or any such application
is filed, or any such proceedings are commenced against Maker and Maker indicates its consent to such proceedings, or an order
or decree is entered by a court of competent jurisdiction appointing such trustee or receiver, or adjudicating Maker bankrupt or
insolvent, or approving the petition in any such proceedings, and such order or decree remains unstayed and in effect for ninety
(90) days.

 

    6

     

    

 

11.            Remedies.
If an Event of Default occurs and is continuing, Payee may, by notice in writing to Maker,
declare the entire Unpaid Balance of this 2020 Note to be due and payable immediately, and upon any such declaration, the entire
Unpaid Balance of this 2020 Note shall become and be immediately due and payable, and Payee may thereupon proceed to protect and
enforce its rights either by suit in equity or by action at law or by other appropriate proceedings, whether for specific performance
(to the extent permitted by law) of any covenant or agreement contained herein or in aid of the exercise of any power granted herein,
or proceed to enforce the payment of this 2020 Note or to enforce any other legal or equitable right of Payee. In the event this
2020 Note is placed in the hands of an attorney for collection or for enforcement, or in the event that Payee incurs any costs
incident to the collection of any indebtedness evidenced hereby, Maker agrees to pay all reasonable attorneys’ fees and expenses,
all court and other costs and the reasonable costs of any other collection efforts. Forbearance to exercise the remedies set forth
herein with respect to any failure or breach of Maker shall not constitute a waiver by Payee of any of such remedies.

 

12.            Expenses.
Except as otherwise provided in this 2020 Note, each of Maker and Payee shall bear its own costs incurred in connection with the
negotiation, documentation and execution of this 2020 Note, the closing of the transactions contemplated herein, and any amendment,
waiver, consent, supplement or modification hereto.

 

13.            Notices.
All notices, requests, consents and other communications required or permitted under this
2020 Note shall be in writing and shall be deemed to have been delivered three (3) days after the date mailed, postage prepaid,
by certified mail, return receipt requested, or on the date personally delivered:

 

	
        If to Maker, to:

         

        Inhibikase Therapeutics, Inc.

        Attn: Chief Executive Officer

        3350 Riverwood Parkway

        Suite 1900

        Atlanta, GA 30339
	
        If to Payee, to:

         

        Flagship Consulting, Inc.

        Frattaroli

        131 Daniel Webster Hwy, #322

        Nashua, NH 03060

 

If to any Payee other than Payee, to such
address as may have been designated by notice given Maker by such Payee. Maker, Payee or any other Payee may designate a different
address by notice given in accordance with the foregoing.

 

14.            Waiver
and Amendment. Any provision of this 2020 Note may be amended, waived or modified
upon the written consent of Maker and Payee.

 

    7

     

    

 

15.            Assignment;
Binding Effect. Payee shall neither be entitled to assign nor assign all or any portion
of its performance obligations under this 2020 Note and any attempted assignment hereof shall be void and of no effect. Subject
to the preceding sentences, this 2020 Note shall be binding upon and shall inure to the benefit of the parties hereto and their
respective heirs, executors, administrators, successors and assigns.

 

16.            Governing
Law. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS
OF THE STATE OF GEORGIA WITHOUT GIVING EFFECT TO CONFLICTS OF LAWS PRINCIPLES.

 

17.            Venue. EACH
OF THE PARTIES HEREBY IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS PROPERTY, TO THE JURISDICTION OF THE COURTS
OF THE STATE OF GEORGIA SITTING IN COBB COUNTY AND OF THE UNITED STATES DISTRICT COURT OF THE DISTRICT OF GEORGIA, AND ANY
APPELLATE COURT FROM ANY THEREOF, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, OR FOR
RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT, AND EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY AGREES THAT
ALL CLAIMS IN RESPECT OF ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN SUCH STATE OR, TO THE EXTENT
PERMITTED BY LAW, IN SUCH FEDERAL COURT. EACH OF THE PARTIES HERETO AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR
PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER
PROVIDED BY LAW. MAKER AND HOLDER HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT IT
MAY LEGALLY AND EFFECTIVELY DO SO, ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY
SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT IN ANY COURT REFERRED TO IN THIS SECTION. EACH OF THE
PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE
MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT. EACH PARTY TO THIS AGREEMENT IRREVOCABLY CONSENTS TO SERVICE OF
PROCESS IN THE MANNER PROVIDED FOR NOTICES IN SECTION 13 OF THIS 2020 Note. NOTHING IN THIS AGREEMENT WILL AFFECT THE
RIGHT OF ANY PARTY TO THIS AGREEMENT TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY LAW.

 

    8

     

    

 

	 	Inhibikase
    Therapeutics, Inc.
	 	 
	 	By:	/s/
    Milton Werner
	 	 	Milton Werner, Ph.D.,
	 	 	Authorized Officer

 

	ACCEPTED AND AGREED TO:	 
	 	 
	Flagship Consulting Inc.	 
	 	 
	By:	/s/ Joseph Frattaroli	 
	 	Joseph Frattaroli, Authorized Officer	 
	 	 
	/s/ Joseph Frattaroli	 
	Joseph Frattaroli, individually	 

 

    9

     

    

 

Exhibit A

 

Schedule

Of

Fees & Costs

 

	Date
    of Statement	Fees
    Accrued To Date	Payments
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

    10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}]]